Wave Life Sciences says WVE-006 trial hits MZ-like AAT phenotype with monthly dosing

• Wave Life Sciences reported updated Phase 1b/2a RestorAATion-2 results for WVE-006 in alpha-1 antitrypsin deficiency, with the data also highlighted earlier today in an oral presentation at the American Thoracic Society International Conference.
• The trial update showed the investigational RNA-editing therapy drove a shift toward a healthier protein profile, supporting the goal of addressing both lung and liver disease with less frequent subcutaneous dosing.
• Wave also cited signs that treatment may restore patients’ ability to raise protective protein levels during acute illness, a functional effect not achieved by current standard therapy.
• The company is targeting FDA feedback on a potential accelerated approval pathway in mid-2026, setting up a key regulatory inflection point for the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605181630PRIMZONEFULLFEED9722358) on May 18, 2026, and is solely responsible for the information contained therein.